igf 1 lr3 mechanism of action About IGF-1R | Lonigutamab LONG® R³ IGF-I
Description
New York, NY, USA: 2017
The POI is applied as a mixed solution with various contaminants typically from a cell extract or culture supernatant in the buffered aqueous mobile phase whereby it forms a non-covalent complex with the immobilized ligand
Overexpression of DNA polymerase iota (Pol) in esophageal squamous cell carcinoma
A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients
